MX367070B - Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. - Google Patents

Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.

Info

Publication number
MX367070B
MX367070B MX2015002452A MX2015002452A MX367070B MX 367070 B MX367070 B MX 367070B MX 2015002452 A MX2015002452 A MX 2015002452A MX 2015002452 A MX2015002452 A MX 2015002452A MX 367070 B MX367070 B MX 367070B
Authority
MX
Mexico
Prior art keywords
gemicitabine
bladder
treatment
methods
drug delivery
Prior art date
Application number
MX2015002452A
Other languages
English (en)
Other versions
MX2015002452A (es
Inventor
Giesing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2015002452A publication Critical patent/MX2015002452A/es
Publication of MX367070B publication Critical patent/MX367070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/04—General characteristics of the apparatus implanted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/16—Male reproductive, genital organs
    • A61M2210/166—Prostate

Abstract

Se proporcionan métodos, dispositivos y medicamentos que incluyen un fármaco, para su uso en el tratamiento de la próstata mediante la administración local del fármaco en la vejiga de un paciente para lograr una concentración sostenida del fármaco en la orina en la vejiga, suficiente para producir una concentración terapéutica del fármaco en la próstata. El fármaco se puede administrar a la vejiga desde un dispositivo de administración de fármaco intravesical insertado en la vejiga, donde el dispositivo libera el fármaco de forma continua en la orina en la vejiga durante un período prolongado de horas o días.
MX2015002452A 2012-08-31 2013-09-03 Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. MX367070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696029P 2012-08-31 2012-08-31
PCT/US2013/057841 WO2014036556A2 (en) 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of prostate

Publications (2)

Publication Number Publication Date
MX2015002452A MX2015002452A (es) 2015-06-05
MX367070B true MX367070B (es) 2019-08-05

Family

ID=49162284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002452A MX367070B (es) 2012-08-31 2013-09-03 Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.

Country Status (14)

Country Link
US (2) US9636488B2 (es)
EP (1) EP2890386A2 (es)
JP (1) JP6309009B2 (es)
KR (2) KR20150043508A (es)
CN (2) CN112516154A (es)
AU (1) AU2013308465B2 (es)
BR (1) BR112015004110A2 (es)
CA (1) CA2882575C (es)
IL (1) IL237300B (es)
IN (1) IN2015DN01560A (es)
MX (1) MX367070B (es)
RU (1) RU2678308C2 (es)
SG (1) SG11201501483XA (es)
WO (1) WO2014036556A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516154A (zh) 2012-08-31 2021-03-19 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
AU2015226901B2 (en) * 2014-03-06 2020-05-14 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US10675289B2 (en) * 2014-10-02 2020-06-09 University Of Maryland, Baltimore Methods of treating pancreatic cancer
US20190388338A1 (en) 2016-05-06 2019-12-26 Taris Biomedical Llc Method of treating lower tract urothelial cancer
SG11201913251VA (en) * 2017-07-25 2020-01-30 Taris Biomedical Llc Methods of treating tumor metastasis
US10792297B2 (en) 2017-11-08 2020-10-06 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
WO2020028554A1 (en) 2018-08-01 2020-02-06 Taris Biomedical Llc Methods of treating overactive bladder using trospium
EP3924521A4 (en) 2019-02-15 2023-03-29 IncellDx, Inc. BLADDER-ASSOCIATED SPECIMEN ASSAY, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
US20040260272A1 (en) 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DE102005020314A1 (de) * 2005-05-02 2006-11-09 Infineon Technologies Ag Spannungsversorgungsanordnung zur Versorgung einer ersten elektrischen Last und Verfahren zum Bereitstellen einer elektrischen Leistung
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR20090108086A (ko) * 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
BRPI0820800B8 (pt) 2007-12-11 2021-06-22 Massachusetts Inst Technology dispositivo médico implantável para liberação controlada de droga
BRPI0911098A2 (pt) 2008-04-04 2015-10-06 Lipella Pharmaceuticals Inc formulação lipossomal e método para tratamento de bexiga hiperativa.
JP2011528275A (ja) * 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
CN102176931B (zh) 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
EA023156B1 (ru) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Устройство для доставки лекарств
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
ES2867399T3 (es) 2009-12-17 2021-10-20 Taris Biomedical Llc Dispositivo implantable con tolerabilidad intravesical
DK2525777T3 (da) 2010-01-20 2019-07-01 Urogen Pharma Ltd Materiale og fremgangsmåde til at behandle interne hulrum
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
LT2600800T (lt) 2010-08-05 2021-01-11 Taris Biomedical Llc Ureteralinio stento pavidalo vaisto vartojimo įtaisas ir rinkinys
EP2624875A1 (en) 2010-10-06 2013-08-14 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
CA2825399A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
CN112516154A (zh) 2012-08-31 2021-03-19 塔里斯生物医药公司 用于治疗前列腺的药物递送系统和方法
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
MX2015003110A (es) 2012-09-18 2015-06-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
RU2669407C2 (ru) 2013-03-15 2018-10-11 ТАРИС Биомедикал ЛЛК Устройства для доставки лекарственных средств и способы доставки лекарственных средств
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
AU2015226901B2 (en) 2014-03-06 2020-05-14 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Also Published As

Publication number Publication date
CN104812395A (zh) 2015-07-29
CN112516154A (zh) 2021-03-19
IL237300B (en) 2020-02-27
RU2678308C2 (ru) 2019-01-25
RU2015109298A (ru) 2016-10-20
BR112015004110A2 (pt) 2017-07-04
AU2013308465B2 (en) 2018-05-17
MX2015002452A (es) 2015-06-05
EP2890386A2 (en) 2015-07-08
WO2014036556A3 (en) 2014-04-17
JP2015528469A (ja) 2015-09-28
KR102383496B1 (ko) 2022-04-08
US9636488B2 (en) 2017-05-02
US20150165177A1 (en) 2015-06-18
WO2014036556A2 (en) 2014-03-06
KR20200120774A (ko) 2020-10-21
IN2015DN01560A (es) 2015-07-03
US20170203085A1 (en) 2017-07-20
SG11201501483XA (en) 2015-03-30
US10406335B2 (en) 2019-09-10
AU2013308465A1 (en) 2015-03-05
JP6309009B2 (ja) 2018-04-11
IL237300A0 (en) 2015-04-30
CA2882575A1 (en) 2014-03-06
KR20150043508A (ko) 2015-04-22
CA2882575C (en) 2020-05-26

Similar Documents

Publication Publication Date Title
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
WO2014197632A3 (en) Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2012109022A3 (en) Medical fluid delivery device programming
WO2012037355A3 (en) Photodynamic therapy system, device and associated method of treatment
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
WO2011156286A3 (en) Stimulation therapy for bladder dysfunction
WO2012002760A3 (ko) 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
MX2015007714A (es) Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
GB201111485D0 (en) Drug composition and its use in therapy
WO2012023623A3 (ja) ハンター症候群の治療剤
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX2014000777A (es) Cateter, en particular cateter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la prostata.
WO2011133957A3 (en) Devices for delivering neuro-electro-adaptive therapy (neat)
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
EA201391689A1 (ru) Система доставки лекарственного средства
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.

Legal Events

Date Code Title Description
FG Grant or registration